For the Inventor, By the Inventor

Enter assignee name

Athens, GA, United States of America

Noramco Gmbh

USPTO Granted Patents = 25

% Expired Patents = 16.0

EPO Patents = 5

Trademarks = 1

Forward Citations = 276

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Wen-Chun Zhang (5 out of 7 patents)

Douglas Phillip Cox (3 out of 3 patents)

D Phillip Cox (3 out of 5 patents)

4. Nicholas M Vernon (3 out of 11 patents)

5. Jessica Cardot (2 out of 2 patents)

6. Jasper Kaiser (2 out of 2 patents)

7. Ulrich Weigl (2 out of 13 patents)

8. Aeri Park (2 out of 8 patents)

9. Yong Zhang (2 out of 3 patents)

10. Karen E James (2 out of 2 patents)

11. Juan L Navia (2 out of 21 patents)

12. Robert E Walkup (2 out of 7 patents)

13. Petinka I Vlahova (1 out of 27 patents)

14. Joshua Sasine (1 out of 1 patent)

15. Paul Nichols (1 out of 1 patent)

Core Competencies:

Hydrocodone

Lisdexamfetamine

Morphinan Alkaloids

Cannabidiol

Opioid Compounds

Oxymorphone

Nalbuphine

Oxycodone

Sucrose Derivatives

Phthalaldehydes

Crystalline Forms

Selective Reduction

25 patents: Sort by Forward Citations

1. 11155548 - Hydrocodone base and methods for its purification (2021-10-26),

2. 11136318 - Processes for the preparation of aryl hydrocarbon receptor ligands (2021-10-05),

3. 10626120 - N-demethylation of morphinan alkaloids (2020-04-21),

4. 10544434 - Process for the preparation of lisdexamfetamine and related derivatives (2020-01-28),

5. 10406153 - Process for the preparation of benzhydrocodone hydrochloride (2019-09-10),

6. 10287296 - Process for the preparation of (S)-2-((4R,4aS,6R,7R,7aR,12bS)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol (2019-05-14),

7. 10155771 - Selective reduction of morphinan alkaloids (2018-12-18),

8. 10059683 - Process for the production of cannabidiol and delta-9-tetrahydrocannabinol (2018-08-28),

9. 10005791 - O-demethylating process of methoxy substituted morphinan-6-one derivatives (2018-06-26),

10. 9701688 - Process for the preparation of opioid compounds (2017-07-11),

11. 9701687 - Process for the preparation of opioid compounds (2017-07-11),

12. 8563571 - Crystalline forms of oxymorphone hydrochloride (2013-10-22),

13. 8536191 - Crystalline and amorphous forms of nalbuphine hydrochloride (2013-09-17),

14. 8058439 - Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone (2011-11-15),

15. 7906647 - Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone (2011-03-15),

Company Overview

Noramco GmbH is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and advanced drug delivery systems. The company focuses on innovative solutions that enhance therapeutic efficacy and patient compliance. With a strong emphasis on research and development, Noramco is dedicated to advancing healthcare through its expertise in chemical synthesis and formulation technologies, serving clients across various global markets.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

25 Patents

#2 in Athens, GA

#256 in Georgia

#13,350 in US

#25,681 in the World

Athens, GA, United States of America

Noramco Gmbh

Forward Citations = 276

53 inventors:

Wen-Chun Zhang (5 out of 7 patents)

Douglas Phillip Cox (3 out of 3 patents)

D Phillip Cox (3 out of 5 patents)

4. Nicholas M Vernon (3 out of 11 patents)

5. Jessica Cardot (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Noramco Gmbh. Retrieved from https://idiyas.com/company/noramco

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…